Evaluation of Her-2 expression in colorectal carcinoma in patients undergoing colectomy in Imam Khomeini Hospital of Ahvaz

Document Type : Original Article

Author

dr

Abstract

Objective: The aim of this study was to evaluate the expression of Her2 protein in patients with colorectal carcinoma in order to better understand the pathophysiology and behavior of inflammatory factors in this disease.
Materials and Methods: In this cross-sectional descriptive study, tissue paraffin blocks of patients referring to Imam Khomeini teaching hospitals with pathological diagnosis of colorectal cancer were evaluated. Clinical and demographic data of patients were extracted from hospital records. Anti Her-2 monoclonal antibody was used for immunohistochemical staining.
Results: In this study, 31 patients with colorectal cancer (mean age 65.1 (range 33 to 89)) were evaluated. Most tumors had grade G2 (54.8%). Tumor stage pt3 was also seen in more than half of cases. Lymph node involvement was observed in 29% of cases. The mean staining area was 34.6% (range 2 to 78%). Her2 staining area in was 30.65% (range 2 to 85%). More than a quarter of patients were negative and only 6.5% had a strong positive reaction. Immunohistochemical expression of Her2 marker was not significantly correlated with other pathological characteristics of colorectal tumor including disease grade, stage of disease and metastasis to lymph nodes.
Conclusion :
Overall, the findings of this study indicate that more than 70% of colorectal patients show Her2 expression. However, our findings showed no association between Her2 marker and other tumor pathologic variables.

Keywords

References

 
1-McCormick D, Kibbe PJ, Morgan SW. Colon cancer: prevention, diagnosis, treatment. Gastroenterol Nurs 2002; 25(5): 204-11.
2-Gayet J, Zhou XP, Duval A, Rolland S, Hoang JM, Cottu P, et al. Extensive characterization of genetic alterations in a series of human colorectal cancer cell lines. Oncogene 2001; 20(36): 5025-32.
3-Kinzler KW, Nilbert MC, Su LK, Vogelstein B, Bryan TM, Levy DB, et al. Identification of FAP locus genes from chromosome 5q21. Science 1991; 253(5020): 661-5.
4-Nishisho I, Nakamura Y, Miyoshi Y, Miki Y, Ando H, Horii A, et al. Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients. Science 1991; 253(5020): 665-9.
5-Gutierrez C, Schiff R . HER2: biology, detection, and clinical implications. Arch Pathol Lab Med 2011;135:55–62.
6-Arteaga CL, Engelman JA . ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell 2014;25:282–303.
7-Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783–792.
8-Bang YJ, Van Cutsem E, Feyereislova A et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376:687–697.
9-Network CGA. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012;487:330–337.
10-Song Z, Deng Y, Zhuang K et al. Immunohistochemical results of HER2/neu protein expression assessed by rabbit monoclonal antibodies SP3 and 4B5 in colorectal carcinomas. Int J Clin Exp Pathol 2014;7:4454–4460.
11-Andre T, Boni C, Navarro M, Tabernero J, Hickish T, et al. (2009) Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 27: 3109–3116.
12-Lech G, Slotwinski R, Krasnodebski IW (2014) The role of tumor markers and biomarkers in colorectal cancer. Neoplasma 61: 1–8.
13-Budinska E, Popovici V, Tejpar S, D'Ario G, Lapique N, et al. (2013) Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancer. J Pathol 231: 63–76.
14-Prins MJ, Ruurda JP, van Diest PJ, van Hillegersberg R, Ten Kate FJ (2013) The significance of the HER-2 status in esophageal adenocarcinoma for survival: an immunohistochemical and an in situ hybridization study. Ann Oncol 24: 1290–1297.
15-Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, et al. (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351: 337–345.
16-Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, et al. (2008) K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359: 1757–1765.
17-Van Cutsem E, Kohne CH, Lang I, Folprecht G, Nowacki MP, et al. (2011) Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 29: 2011–2019.
18-Penault-Llorca F, Bilous M, Dowsett M, Hanna W, Osamura RY, Ruschoff J, et al. Emerging technologies for assessing HER2 amplification. Am J Clin Pathol. 2009; 132(4) : 539 -48
19-Kavanagh DO, Chambers G, O'Grady L, Barry KM, Waldron RP, Bennani F, et al. Is overexpression of HER-2 a predictor of prognosis in colorectal cancer? BMC Cancer. 2009; 9 : 1
20-Wu QB, Sun GP. Expression of COX-2 and HER-2 in colorectal cancer and their correlation. World J Gastroenterol. 2015; 21(20) : 6206 -14 
21-Seo AN, Kwak Y, Kim DW, Kang SB, Choe G, Kim WH, et al. HER2 status in colorectal cancer: its clinical significance and the relationship between HER2 gene amplification and expression. PLoS One. 2014; 9(5)
22-Ramieri MT, Murari R, Botti C, Pica E, Zotti G, Alo PL. Detection of HER2 amplification using the SISH technique in breast, colon, prostate, lung and ovarian carcinoma. Anticancer Res. 2010; 30(4) : 1287 -92
23-Wang XY, Zheng ZX, Sun Y, Bai YH, Shi YF, Zhou LX, Yao YF, Wu AW, Cao DF. Significance of HER2 protein expression and HER2 gene amplification in colorectal adenocarcinomas. World journal of gastrointestinal oncology. 2019 Apr 15;11(4):335.
24-Wei Q, Zhang Y, Gao J, Li J, Li J, Li Y, Zhou J, Lu M, Gong J, Zhang X, Shen L. Clinicopathological characteristics of HER2-positive metastatic colorectal cancer and detection of HER2 in plasma circulating tumor DNA. Clinical colorectal cancer. 2019 May 13.
25-Stahler A, Heinemann V, Neumann J, Crispin A, Schalhorn A, Stintzing S, Giessen-Jung C, Fischer von Weikersthal L, Vehling-Kaiser U, Stauch M, Quietzsch D. Prevalence and influence on outcome of HER2/neu, HER3 and NRG1 expression in patients with metastatic colorectal cancer. Anti-cancer drugs. 2017 Aug 1;28(7):717-22.
26-Kwon MJ, Soh JS, Lim SW, Kang HS, Lim H. HER2 as a limited predictor of the therapeutic response to neoadjuvant therapy in locally advanced rectal cancer. Pathology-Research and Practice. 2019 May 1;215(5):910-7.
Jundishapur Scientific Medical Journal
Volume 19, Issue 1 - Serial Number 124
March and April 2021
Pages 27-36

Files

History

  • Receive Date: 17 January 2020
  • Accept Date: 01 March 2020

Share

How to cite

Statistics